Pharma tariffs may go as high as 250%, says Trump

US President Donald Trump said Tuesday that upcoming tariffs on imported pharmaceuticals could go as high as 250 percent — after starting at a lower level — adding he plans to unveil fresh duties on foreign semiconductors.

“We’ll be putting (an) initially small tariff on pharmaceuticals, but in one year, one-and-a-half years, maximum, it’s going to go to 150 percent and then it’s going to go to 250 percent because we want pharmaceuticals made in our country,” Trump said in an interview on CNBC.

He did not say what the initial tariff rate on pharmaceuticals would be.

Trump said he would also announce tariffs on semiconductors and chips in the “next week or so” without elaborating.

The US president has threatened debilitating tariffs on the drug industry in an effort to force manufacturing back into the US. Trump recently demanded major suppliers of medicines drastically cut costs or face additional, unspecified penalties.

Related Posts

Rajasthan Bans 7 Sub-Standard Medicines

Prioritising public health and patient safety, the Commissionerate of Food Safety and Drug Control, Rajasthan, has issued an alert regarding seven medicines and declared them “Not of Standard Quality”. Prioritising…

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

To Eat or not to Eat, if this Dilemma is ‘Eating’ you, ‘Eat’ this Book

To Eat or not to Eat, if this Dilemma is ‘Eating’ you, ‘Eat’ this Book

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

Rajasthan Bans 7 Sub-Standard Medicines

Rajasthan Bans 7 Sub-Standard Medicines

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more